Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy

SIMPLE SUMMARY: FMC63-CAR-T cell therapy, an immunotherapy against CD19 protein expressed on malignant B cells, is effective in diffuse large B-cell lymphoma (r/r DLBCL) with complete response in half of the treated patients. Remarkably, there are two germline CD19 antigen variants due to the single...

Descripción completa

Detalles Bibliográficos
Autores principales: Seipel, Katja, Abbühl, Mariesol, Bacher, Ulrike, Nilius, Henning, Daskalakis, Michael, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252965/
https://www.ncbi.nlm.nih.gov/pubmed/37297020
http://dx.doi.org/10.3390/cancers15113058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252965/
https://www.ncbi.nlm.nih.gov/pubmed/37297020
http://dx.doi.org/10.3390/cancers15113058

Ejemplares similares